Response to the different therapeutic schemes used in the treatment of lupus nephropathy
DOI:
https://doi.org/10.51481/amc.v47i3.192Keywords:
Systemic Lupus Erythematosus, Lupus Nephritis, treatment, Prednisone, azatioprina, cyclophosphamideAbstract
AIM:Lupus nephritis is considered the prototype forimmune complex-mediated glomerulonephritis. There is agreat variety of clinical manifestations and histologycchanges associated with this disorder.
Patients are at high risk of progressive decline of renal func-tion as a result of organ injury secondary to the interactionof immune and chronic sclerosing mechanisms.Monitoring activity parameters, renal protein excretion, andurinary sediment, make it easier for the recognition of theprognosis and treatment of this disease.
This investigation was made in order to compare theresponse of patients diagnosed with lupus nephritis to thedifferent therapeutic regimens used for the treatment of thisentity at the Rheumatology Service of the Hospital Mexico.
Methods:A retrospective, cross sectional study was made,of the clinical files of patients diagnosed with lupus nephri-tis at seen the Rheumatology Service of the HospitalMexico from 1990 to 1999. A comparison was made of theresponse to the different therapeutic regimens used fortreatment in each patient.
Results:There were 65 patients diagnosed with lupusnephritis, with a female/male ratio was of 5/1. The majori-ty of the group was from 20 to 40 years. The most commonhystologic finding on renal biopses was type IV lupusnephritis. From all the therapeutic regimens, the one thatincluded prednisone and cyclophosphamide was morefrequently used than any other (52,3%). The use of this regimen showed improvement in all of the analyzed clinicalparameters. Cyclophosphamide was the drug that producedmore adverse effects.
The use of prednisone- cyclophosphamide demonstratedmajor efficacy in the treatment of patients with lupusnephritis.
Downloads
References
Mok CC, Wong RWS, Lai KN. Treatment of severe proliferativelupus nephritis: the current state. Ann Rheum Dis 2003; 62: 799-800.
Klippel JH, Weyand CM, Wortmann RL. Primer on the rheumaticdiseases. Atlanta: Arthritis Foundation, 1997.
Pedrosa MF, Beaumont GH, Sánchez JL, Mola EM, Marqués AO,García PB et al. Manual de enfermedades reumáticas. Madrid:Sociedad Española de Reumatología, 1996.
Kuiper-Geertsma DG, Derksen RH. Newer drugs for the treatment oflupus nephritis. Drugs 2003; 63: 167-180.
Hübscher O. Lupus como uno de los temas centrales del CongresoAnual del Colegio Americano de Reumatología. Publicaciones deALUA. 1997 Nov. Se consigue en: URL:http://www.drwebsa.com.ar/alua/temac.htm
Mok CC, Lai KN. Mycophenolate Mofetil in lupus glomerulonephri-tis. Am J Kidney Dis 2002; 40: 447-457
Hejaili FF, Moist LM, Clark WF. Treatment of lupus nephritis. Drugs2003; 63: 257-274.
Tumlin JA. Lupus nephritis: novel immunosuppresive modalities andfuture directions. Semin Nephrol 1999; 19: 67-76.
Elizondo PM. Introducción a la reumatología. México: SociedadMexicana de Reumatología, 1997.
Fauci AS, Branwald E, Isselbacher KJ, Wilson JD, Martin JB, KasperDL, et al. Harrison. Principios de Medicina Interna. México: McGraw-Hill, 1998.
Balcells A. La clínica y el laboratorio. España: Masson, 1997.
Pirani CL, Pollak VE. The natural history of the renal manifestationsof systemic lupus erythematosus. J Am Soc Nephrol 1997; 63: 1189-1190.
Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al.Efficacy of mycophenolate mofetil in patients with diffuse prolifera-tive lupus nephritis. N Engl J Med 2000; 343: 1156.
Austin HA, Boumpas DT. Treatment of lupus nephritis. SeminNephrol 1996; 16:527-535.
Steinberg AD, Gourley M. Cyclophosphamide in lupus nephritis. JRheumatol 1995; 22: 1812-1814.
Fox DA, Mc Cune WJ. Inmmunosupressive drug therapy of systemiclupus erythematosus. Rheum Dis Clin North Am 1994; 20: 265-286.
Balow JE, Boumpas DT, Fessler BJ, Austin HA. Management oflupus nephritis. Kidney Int 1996; 49: 90-91.
Falk RJ. Treatment of lupus nephritis. A work in progress. N Engl JMed 2000; 343: 1182-1183.
Berden JM. Lupus nephritis. Kidney Int 1997; 52: 543-547.
Kelley WN, Harris ED, Ruddy S, Sledge CB. Textbook of rheumatol-ogy. Philadelphia: W.B. Saunders Company, 1993.
Donadio JV, Glassock RJ. Immunosupressive drug therapy in lupusnephritis. Am J Kidney Dis 1993; 21: 239-241.
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
